Magnetic energy similar to what is used in an (MRI) is used to stimulate the areas of the brain that are sluggish and causing depressed mood.
Clinical trials have demonstrated the safety and effectiveness of NeuroStar® TMS Therapy in treating patients who have not benefited from prior antidepressant medication. NeuroStar TMS Therapy was studied in adult patients suffering from Major Depressive Disorder, all of whom had not received satisfactory improvement with previous treatments.
NeuroStar is a safe, effective, non-drug depression treatment that uses focused magnetic pulses, similar in strength to an MRI, to revitalize connections in an area of the brain involved in regulating your mood. When these connections are reawakened, many people experience measurable relief from their depression.
In a study of “real-world” outcomes (meaning actual NeuroStar patients), 83% of people who completed the full NeuroStar treatment cycle experienced a measurable decrease in the severity of their depression, and 62% of those completing treatment saw full remission – meaning their depression eﬀectively “went away.” 
While there may be some minor discomfort at the treatment site (where the device touches your head), it generally subsides within the ﬁrst week or treatment. There is no sedation, or impact on your alertness. You can read, watch TV, or talk with your treatment coordinator during your session, and you can drive home immediately after treatment.
Over 300 million people have insurance plans that cover NeuroStar, including Medicare and Tricare. Conditions and coverage can vary by insurance company, and your NeuroStar Team Lead will help you determine your beneﬁts and coverage. We also oﬀer cash-pay and patient ﬁnancing options if desired, talk with your NeuroStar representative for more details.
NeuroStar is FDA-cleared for adults with Major Depressive Disorder who have not found relief from antidepressant medications. A NeuroStar leader will walk you through the full qualiﬁcations for treatment during your initial consultation.
 Sackeim HA, et al. (2020) J. Aﬀect. Disord. 277:65-74. Based on a real-world, retrospectivestudy using CGI-S and a sample size of 615 patients.© 2022 Neuronetics, Inc., Malvern, PA | 53-51670-000 Rev A• Covered by most insurances• FDA-clear